pentoxifylline has been researched along with Skin Neoplasms in 18 studies
Skin Neoplasms: Tumors or cancer of the SKIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pentoxifylline (PTX), a non-specific phosphodiesterase inhibitor is known to inhibit the growth of various cancer cells including melanoma." | 7.83 | Pentoxifylline triggers autophagy via ER stress response that interferes with Pentoxifylline induced apoptosis in human melanoma cells. ( Dutta, RK; Ishaq, M; Khan, MA; Majumdar, S; Sharma, G; Sharma, K, 2016) |
| " Pentoxifylline (PTX), a methyl xanthine derivative, inhibits B16F10 melanoma lung homing by inhibiting F10 invasion, MMP secretion and adhesion to matrix components." | 7.74 | Pentoxifylline impedes migration in B16F10 melanoma by modulating Rho GTPase activity and actin organisation. ( Dua, P; Gude, RP, 2008) |
| "Melanoma is the most common malignant skin cancer, appears indestructible and is notoriously resistant to all current modalities of cancer treatment strategies." | 5.38 | Preclinical evaluation of the antimetastatic efficacy of Pentoxifylline on A375 human melanoma cell line. ( Gude, RP; Kamran, MZ, 2012) |
| " The present studies were performed to examine the effects of acute and chronic administration of pentoxifylline on TPA-induced cutaneous inflammation in female Sencar mice treated once with 10 micrograms TPA and also to determine the ability of pentoxifylline to inhibit the tumor promotion process in mice treated with a single application of 25 nmol 7,12-dimethylbenz[a]anthracene (DMBA) followed for 8 weeks by twice weekly topical application of TPA." | 5.29 | Inhibition of pro-inflammatory cytokine gene expression and papilloma growth during murine multistage carcinogenesis by pentoxifylline. ( Long, BW; Oberyszyn, TM; Robertson, FM; Ross, MS; Tober, KL, 1996) |
| "Isolated limb perfusion (ILP) with recombinant human tumor necrosis factor-alpha (rhTNF-alpha) and melphalan harbors the risk of septic shock-like syndrome." | 5.10 | Pentoxifyllin attenuates the systemic inflammatory response induced during isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan. ( Hohenberger, P; Kettelhack, C; Latz, E; Rezaei, AH; Schlag, PM; Schumann, R, 2003) |
| "Pentoxifylline (PTX), a non-specific phosphodiesterase inhibitor is known to inhibit the growth of various cancer cells including melanoma." | 3.83 | Pentoxifylline triggers autophagy via ER stress response that interferes with Pentoxifylline induced apoptosis in human melanoma cells. ( Dutta, RK; Ishaq, M; Khan, MA; Majumdar, S; Sharma, G; Sharma, K, 2016) |
| " Pentoxifylline (PTX), a methyl xanthine derivative, inhibits B16F10 melanoma lung homing by inhibiting F10 invasion, MMP secretion and adhesion to matrix components." | 3.74 | Pentoxifylline impedes migration in B16F10 melanoma by modulating Rho GTPase activity and actin organisation. ( Dua, P; Gude, RP, 2008) |
| "Antiphospholipid antibody syndrome is an autoimmune disorder associated with pregnancy complications, venous and/or arterial thrombosis and the presence of antiphospholipid antibodies." | 1.42 | Reactive angioendotheliomatosis as a presenting cutaneous manifestation of Hughes syndrome. ( Jamale, V; Kale, M; Nikam, B; Shah, S, 2015) |
| "Pentoxifylline was able to ameliorate this nephrotoxic condition as suggested by the change in levels of membrane bound ATPases, MDA and GSH." | 1.40 | Carboplatin-induced Fanconi-like syndrome in rats: amelioration by pentoxifylline. ( Bhamre, P; Gandhi, H; Khakhariya, R; Rajput, SJ; Rathod, SP; Trivedi, J; Variya, B, 2014) |
| "Melanoma is the most common malignant skin cancer, appears indestructible and is notoriously resistant to all current modalities of cancer treatment strategies." | 1.38 | Preclinical evaluation of the antimetastatic efficacy of Pentoxifylline on A375 human melanoma cell line. ( Gude, RP; Kamran, MZ, 2012) |
| " The present studies were performed to examine the effects of acute and chronic administration of pentoxifylline on TPA-induced cutaneous inflammation in female Sencar mice treated once with 10 micrograms TPA and also to determine the ability of pentoxifylline to inhibit the tumor promotion process in mice treated with a single application of 25 nmol 7,12-dimethylbenz[a]anthracene (DMBA) followed for 8 weeks by twice weekly topical application of TPA." | 1.29 | Inhibition of pro-inflammatory cytokine gene expression and papilloma growth during murine multistage carcinogenesis by pentoxifylline. ( Long, BW; Oberyszyn, TM; Robertson, FM; Ross, MS; Tober, KL, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (33.33) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 7 (38.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kamran, MZ | 2 |
| Gude, RP | 3 |
| Criado, PR | 1 |
| Alavi, A | 1 |
| Halpern, I | 1 |
| Sotto, MN | 1 |
| Kirsner, RS | 1 |
| Khakhariya, R | 1 |
| Rathod, SP | 1 |
| Gandhi, H | 1 |
| Variya, B | 1 |
| Trivedi, J | 1 |
| Bhamre, P | 1 |
| Rajput, SJ | 1 |
| Nikam, B | 1 |
| Shah, S | 1 |
| Kale, M | 1 |
| Jamale, V | 1 |
| Sharma, K | 1 |
| Ishaq, M | 1 |
| Sharma, G | 1 |
| Khan, MA | 1 |
| Dutta, RK | 1 |
| Majumdar, S | 2 |
| Rishi, L | 1 |
| Gahlot, S | 1 |
| Kathania, M | 1 |
| Stoopler, ET | 1 |
| Musbah, T | 1 |
| Hohenberger, P | 1 |
| Latz, E | 1 |
| Kettelhack, C | 1 |
| Rezaei, AH | 1 |
| Schumann, R | 1 |
| Schlag, PM | 1 |
| Wheeler, DL | 1 |
| Ness, KJ | 1 |
| Oberley, TD | 1 |
| Verma, AK | 1 |
| Dua, P | 1 |
| Weiss, JM | 1 |
| Vanscheidt, W | 1 |
| Pilarski, KA | 1 |
| Weyl, A | 1 |
| Peschen, M | 1 |
| Schöpf, E | 1 |
| Vestweber, D | 1 |
| Simon, JC | 1 |
| Dezube, BJ | 1 |
| Pardee, AB | 1 |
| Chapman, B | 1 |
| Beckett, LA | 1 |
| Korvick, JA | 1 |
| Novick, WJ | 1 |
| Chiurco, J | 1 |
| Kasdan, P | 1 |
| Ahlers, CM | 1 |
| Ecto, LT | 1 |
| Samlaska, CP | 1 |
| Winfield, EA | 1 |
| Sensky, PL | 1 |
| Prise, VE | 1 |
| Ward, AE | 1 |
| Hirst, DG | 1 |
| Robertson, FM | 1 |
| Ross, MS | 1 |
| Tober, KL | 1 |
| Long, BW | 1 |
| Oberyszyn, TM | 1 |
| Lazarczyk, M | 1 |
| Grzela, T | 1 |
| Korczak-Kowalska, G | 1 |
| Józwiak, J | 1 |
| de Prost, Y | 1 |
| Teillac, D | 1 |
| Bodemer, C | 1 |
| Enjolras, O | 1 |
| Nihoul-Fekete, C | 1 |
| de Prost, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pentoxifylline (Trental) as a Modulator of Tumor Necrosis Factor and of HIV Replication in Patients With AIDS[NCT00000646] | Phase 1 | 54 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for pentoxifylline and Skin Neoplasms
| Article | Year |
|---|---|
Pentoxifylline.
Topics: Animals; Blood Coagulation; Connective Tissue; Dose-Response Relationship, Drug; Drug Interactions; | 1994 |
1 trial available for pentoxifylline and Skin Neoplasms
| Article | Year |
|---|---|
Pentoxifyllin attenuates the systemic inflammatory response induced during isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chemothera | 2003 |
16 other studies available for pentoxifylline and Skin Neoplasms
| Article | Year |
|---|---|
Pentoxifylline inhibits melanoma tumor growth and angiogenesis by targeting STAT3 signaling pathway.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Humans | 2013 |
Unilateral livedoid vasculopathy associated with involutional phase of cutaneous infantile hemangioma: the connection to coagulation disorders.
Topics: Adolescent; Aspirin; Biopsy; Blood Coagulation Disorders; Blood Coagulation Tests; Diagnosis, Differ | 2013 |
Carboplatin-induced Fanconi-like syndrome in rats: amelioration by pentoxifylline.
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Agents; Blood Urea Nitrogen; Carboplatin; Creatin | 2014 |
Reactive angioendotheliomatosis as a presenting cutaneous manifestation of Hughes syndrome.
Topics: Abortion, Habitual; Adult; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Antiphospholip | 2015 |
Pentoxifylline triggers autophagy via ER stress response that interferes with Pentoxifylline induced apoptosis in human melanoma cells.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Autophagy-Related Protein 5; Calcium; Calcium Chelating | 2016 |
Pentoxifylline induces apoptosis in vitro in cutaneous T cell lymphoma (HuT-78) and enhances FasL mediated killing by upregulating Fas expression.
Topics: Apoptosis; Cell Line, Tumor; Cells, Cultured; Fas Ligand Protein; fas Receptor; Gene Expression Regu | 2009 |
Recurrent aphthous stomatitis.
Topics: Administration, Oral; Adult; Follow-Up Studies; Humans; Lymphoma, T-Cell, Cutaneous; Male; Pentoxify | 2013 |
Preclinical evaluation of the antimetastatic efficacy of Pentoxifylline on A375 human melanoma cell line.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Prol | 2012 |
Protein kinase Cepsilon is linked to 12-O-tetradecanoylphorbol-13-acetate-induced tumor necrosis factor-alpha ectodomain shedding and the development of metastatic squamous cell carcinoma in protein kinase Cepsilon transgenic mice.
Topics: Animals; Carcinogens; Carcinoma, Squamous Cell; Female; Keratinocytes; Male; Mice; Mice, Inbred C57B | 2003 |
Pentoxifylline impedes migration in B16F10 melanoma by modulating Rho GTPase activity and actin organisation.
Topics: Actins; Animals; Cell Movement; Cyclic AMP-Dependent Protein Kinases; Enzyme Inhibitors; GTPase-Acti | 2008 |
Pentoxifylline inhibits tumor necrosis factor-alpha (TNF alpha)-induced T-lymphoma cell adhesion to endothelioma cells.
Topics: Animals; Cell Adhesion; Cell Line; Lymphangioma; Lymphoma, T-Cell, Cutaneous; Mice; Pentoxifylline; | 1995 |
Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. NIAID AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; beta 2-Microglobulin; Biopterins; Body Weight; CD4-Positi | 1993 |
The effects of pentoxifylline on the relative perfusion of tumours growing in three sites in the mouse.
Topics: Adenocarcinoma; Animals; Blood Viscosity; Cardiac Output; Cecal Neoplasms; Hematocrit; Male; Mammary | 1993 |
Inhibition of pro-inflammatory cytokine gene expression and papilloma growth during murine multistage carcinogenesis by pentoxifylline.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anticarcinogenic Agents; Carcinogens; Cell Division; Fema | 1996 |
Pentoxifylline inhibits perforin-dependent PBMC cytotoxic activity.
Topics: Annexin A5; Cytotoxicity, Immunologic; Hematologic Agents; Humans; K562 Cells; Pentoxifylline; Skin | 2002 |
Successful treatment of Kasabach-Merritt syndrome with pentoxifylline.
Topics: Disseminated Intravascular Coagulation; Female; Forearm; Hemangioma; Humans; Infant; Pentoxifylline; | 1991 |